{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-338097","form_type":"8-K","ticker":"REVB","cik":"0001810560","company_name":"REVELATION BIOSCIENCES, INC.","filed_at":"2026-08-06T20:19:39+00:00","discovered_at":"2026-08-06T20:21:00.308972+00:00","generated_at":"2026-08-06T20:22:28.157400+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Revelation Biosciences Q2 2026 net loss $3.3M; cash $11.5M, runway into Q1 2027","bullets":["Net loss of $3.3M ($0.87 per share) for Q2 2026 vs. $2.4M ($28.04) in Q2 2025.","Cash and cash equivalents $11.5M as of June 30, 2026, up from $10.7M at Dec 31, 2025.","Operating cash burn $2.6M in Q2 2026 vs. $1.9M in Q2 2025.","Phase 2/3 AKI trial startup progressing; independent market assessment shows $94B TAM for Gemini.","Management expects current cash to fund operations through Q1 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-338097","json":"https://secwatch.observer/filing/0001193125-26-338097.json","markdown":"https://secwatch.observer/filing/0001193125-26-338097.md","text":"https://secwatch.observer/filing/0001193125-26-338097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/0001193125-26-338097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1810560/000119312526338097/revb-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:22:28.157400+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}